This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (36)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Connective Tissue Diseases  • Patient Safety/ Medical Error  • Dermatologic Disorders, Other  • Gastroenterology  • Gastrointestinal Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Daihung Jay Duong; G. Thomas Spigel, MD; Richard T. Moxley III, MD; Anthony A. Gaspari, MD

Arch Dermatol. 1999;135:1079-1087.

Background  There is a renewed interest in thalidomide therapy after its surprising effectiveness in treating erythema nodosum leprosum was first published. Thalidomide has subsequently been reported to be effective in treating a number of dermatoses, including cutaneous lupus erythematosus. We examined the efficacy and adverse effects of low-dose, long-term thalidomide monotherapy in 7 patients with various forms of cutaneous lupus erythematosus that were unresponsive to traditional systemic treatments.

Observations  Six of the 7 patients treated with thalidomide after discontinuation of other oral agents had complete or marked resolution of their previously treatment-resistant cutaneous lesions, with an average response time of 2.2 ± 0.8 months. Our cohort of 7 patients with cutaneous lupus erythematosus was treated with thalidomide therapy for an average of 2.4±3.1 years (range, 1 month to 9 years). The most common adverse effects were sedation, constipation, and weight gain. Two patients reported experiencing intermittent shaking episodes, an adverse effect not previously reported in the literature. Four patients reported symptoms of paresthesia, but none was found to be caused by thalidomide-induced peripheral neuropathy.

Conclusions  A low starting dose of thalidomide as a monotherapy with continued sun avoidance is a safe and effective treatment for the various cutaneous manifestations of lupus erythematosus after traditional therapeutic options have failed to control disease. Our experience with low-dose, long-term thalidomide therapy suggests that peripheral neuropathy is not as common as suggested by other studies (up to 50% of patients treated with thalidomide in some series).

From the Olean Medical Group, Olean, NY (Dr Spigel); and Departments of Neurology (Dr Moxley), Dermatology (Dr Gaspari), and Microbiology/Immunology (Dr Gaspari) and Cancer Center (Dr Gaspari), University of Rochester School of Medicine and Dentistry, Rochester, NY. Mr Duong is a medical student at the University of Rochester School of Medicine and Dentistry.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 1999;135(9):1139-1140.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dermatologic and Nondermatologic Uses of Thalidomide
Nasca et al.
The Annals of Pharmacotherapy 2003;37:1307-1320.
ABSTRACT | FULL TEXT  

Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus
Piette et al.
Lupus 2002;11:67-70.
 

Update on therapy -- thalidomide in the treatment of lupus
Karim et al.
Lupus 2001;10:188-192.
ABSTRACT